REGISTER
BRAF Class I vs III NSCLC:Who Benefits From Immunotherapy?| Alessandro Di Federico, WCLC
At WCLC 2026, Dr. Alessandro Di Federico discusses immunotherapy in BRAF class I and class III–mutant NSCLC, including differences in treatment outcomes, patient-selection biomarkers, evidence gaps, and research priorities for ultra-rare BRAF class III subgroups. Dr. Di Federico is a Staff Scientist at Memorial Sloan Kettering Cancer Center.

This WCLC 2026 interview with Dr. Alessandro Di Federico focuses on immunotherapy outcomes and treatment selection in BRAF class I and class III–mutant non-small cell lung cancer.

Organized by the International Association for the Study of Lung Cancer (IASLC), the World Conference on Lung Cancer (WCLC) brings together clinicians, researchers, nurses, and other thoracic oncology professionals to share major advances in lung cancer research and clinical care. WCLC 2026 took place in Seoul, Republic of Korea, from September 12 to 15.

Dr. Alessandro Di Federico is a Staff Scientist at Memorial Sloan Kettering Cancer Center and a medical oncologist specializing in thoracic malignancies, lung cancer biomarkers, and treatment personalization. Dr. Di Federico also serves on the IASLC Career Development Committee.

Key highlights from this clip:

● Evidence gaps in the treatment of BRAF-mutant NSCLC

● Immunotherapy outcomes in class I versus class III BRAF mutations

● Findings in relation to the immunotherapy profile of BRAF V600E-mutant disease

● Clinical and molecular factors guiding patient selection

● Immunotherapy decisions across different treatment lines

● Research priorities for ultra-rare BRAF class III subgroupsThis video is intended for medical education and professional discussion.

0
0
Loading